CoChat

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study

Open access

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Treatment-resistant depression (TRD) is a chronic illness requiring long-term treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of patients with TRD, including SUSTAIN-1 (NCT02493868) and SUSTAIN-3 (NCT02782104). This subgroup analysis of SUSTAIN-3 evaluated patients with TRD who received a second induction (IND) and maintenance treatment with ESK plus oral antidepressant (AD) after a relapse in SUSTAIN-1. METHODS: Patients aged 18-64 years who achieved stable remission or response with ESK and subsequently relapsed after randomization to continue ESK or switch to placebo nasal spray (PBO) in SUSTAIN-1 and entered the IND phase of SUSTAIN-3 were included in this interim analysis. Response (≥50% improvement in total score from baseline for Montgomery-Åsberg Depression Rating Scale [MADRS] and Patient Health Questionnaire 9-item [PHQ-9]), remission (MADRS score ≤12; PHQ-9 total score <5), changes in depression rating scores (measured as mean change from baseline), and safety were evaluated (incidence of treatment-emergent and serious adverse events [AE]). RESULTS: Of the 96 eligible patients who entered IND in SUSTAIN-3, 32 (33.3%) were taking ESK+AD at the time of relapse in SUSTAIN-1 and 64 (66.7%) were taking AD+PBO. Substantial improvements in depressive symptoms were observed over the second IND phase in both groups and were maintained over the optimization/maintenance (OP/M) phase. MADRS response rates following a second IND were 71.9% and 73.4% for previously relapsed (PR) ESK+AD and PR-AD+PBO, respectively; remission rates were 62.5% and 60.9%, respectively. During the IND and OP/M phases, 58.3% and 83.3% of patients experienced a treatment-emergent AE, respectively. No patients discontinued due to an AE during the second IND. CONCLUSIONS: Patients with TRD benefitted from receiving a second IND and maintenance treatment with ESK and no new safety signals were identified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40263-023-01026-3

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 SUSTAIN-3 study design. aStable remission was defined as MADRS total score ≤12 for at least 3 of the last 4 weeks of the optimization phase; stable response was defined as ≥50% reduction in the MADRS total score from baseline in each of the last 2 weeks of the optimization phase but does not meet criteria for stable remission. bBased on CGI-S and tolerability. AD antidepressant, CGI-S Clinical Global Impression-Severity, ESK esketamine nasal spray, OL open label, PR-AD+PBO previously relapsed on an oral AD plus placebo, PR-ESK+AD previously relapsed on ESK plus an oral AD
Fig. 1 SUSTAIN-3 study design. aStable remission was defined as MADRS total score ≤12 for at least 3 of the last 4 weeks of the optimization phase; stable response was defined as ≥50% reduction in the MADRS total score from baseline in each of the last 2 weeks of the optimization phase but does not meet criteria for stable remission. bBased on CGI-S and tolerability. AD antidepressant, CGI-S Clinical Global Impression-Severity, ESK esketamine nasal spray, OL open label, PR-AD+PBO previously relapsed on an oral AD plus placebo, PR-ESK+AD previously relapsed on ESK plus an oral ADCC BY-NC · PubMed Central
Fig. 2 Mean MADRS total scores (LOCF) during the reinduction and optimization/maintenance phases of SUSTAIN-3 among patients who previously experienced relapse in SUSTAIN-1. IND induction, LOCF last observation carried forward, MADRS Montgomery-Åsberg Depression Rating Scale, OP/M optimization/maintenance, PR-AD+PBO previously relapsed on an oral antidepressant plus placebo, PR-ESK+AD previously relapsed on esketamine nasal spray plus an oral antidepressant
Fig. 2 Mean MADRS total scores (LOCF) during the reinduction and optimization/maintenance phases of SUSTAIN-3 among patients who previously experienced relapse in SUSTAIN-1. IND induction, LOCF last observation carried forward, MADRS Montgomery-Åsberg Depression Rating Scale, OP/M optimization/maintenance, PR-AD+PBO previously relapsed on an oral antidepressant plus placebo, PR-ESK+AD previously relapsed on esketamine nasal spray plus an oral antidepressantCC BY-NC · PubMed Central
Fig. 3 Mean PHQ-9 total scores (LOCF) during the reinduction and optimization/maintenance phases of SUSTAIN-3 among patients who previously experienced relapse in SUSTAIN-1. IND induction, LOCF last observation carried forward, OP/M optimization/maintenance, PHQ-9 Patient Health Questionnaire 9-item, PR-AD+PBO previously relapsed on an oral antidepressant plus placebo, PR-ESK+AD previously relapsed on esketamine nasal spray plus an oral antidepressant
Fig. 3 Mean PHQ-9 total scores (LOCF) during the reinduction and optimization/maintenance phases of SUSTAIN-3 among patients who previously experienced relapse in SUSTAIN-1. IND induction, LOCF last observation carried forward, OP/M optimization/maintenance, PHQ-9 Patient Health Questionnaire 9-item, PR-AD+PBO previously relapsed on an oral antidepressant plus placebo, PR-ESK+AD previously relapsed on esketamine nasal spray plus an oral antidepressantCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 27

Metadata

Authors
Castro, M., Wilkinson, S. T., Al Jurdi, R. K., Petrillo, M. P., Zaki, N., Borentain, S., Fu, D. J., Turkoz, I., Sun, L., Brown, B., & Cabrera, P.
Affiliations
  • Janssen Scientific Affairs (United States) (US)
  • Yale University (US)
  • Cytel (United States) (US)
Corresponding author
Castro, Meredith
Venue
CNS Drugs
Published
2023-08
Volume
37
Issue
8
Pages
715-723
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W4385694402
Cited by
25
References
22
Citations by year
2026: 5 · 2025: 8 · 2024: 11 · 2023: 1
FWCI
3.88
Type
journal article
Language
en
Open access
Licence
Locations
  • CNS Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Janssen Scientific Affairs, LLC
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
esketamine nasal spray, treatment-resistant depression, relapse, maintenance therapy, oral antidepressant, long-term treatment, remission, treatment-emergent adverse events, ketamine, antidepressant efficacy and safety, Montgomery-Asberg Depression Rating Scale, PHQ-9, NMDA receptor antagonists
MeSH terms
Adolescent, Adult, Antidepressive Agents, Clinical Trials as Topic, Humans, Ketamine, Middle Aged, Treatment Outcome, Young Adult, Nasal Sprays, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. https://app.cochat.ai/papers/10.1007/s40263-023-01026-3
The paper
Castro, M., Wilkinson, S. T., Al Jurdi, R. K., Petrillo, M. P., Zaki, N., Borentain, S., Fu, D. J., Turkoz, I., Sun, L., Brown, B., & Cabrera, P. (2023). Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. CNS Drugs. https://doi.org/10.1007/s40263-023-01026-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.